Drugs / Meldonium
Meldonium
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07304921 | Apr → Jun 2023 | inherited lipid metabolism disorder | Riga Stradins University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06648902 | Feb 2022 → Sep 2024 | renal cell carcinoma | Kidney Cancer Research Bureau | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01800357 | Jan 2013 → Jun 2014 | ischemic stroke | Xijing Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01831011 | Jul 2008 → Apr 2010 | ischemic stroke | Xijing Hospital | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05939622 | May → Dec 2022 | COVID-19, cognitive disorder, neurocirculatory asthenia | Promomed, LLC | Completed | No outcome recorded |
| Phase 4 | NCT05689827 | Apr → Nov 2022 | COVID-19 | Promomed, LLC | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07568574 | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meldonium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05689827 ↗ |
| Known as | Meldonio | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104708 ↗ |
| Known as | MET-88 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104708 ↗ |
| Known as | mildronate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01831011 ↗ |
| Known as | Quaterine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104708 ↗ |
| Action | Inhibit | “Meldonium is a fatty acid oxidation inhibitor” NCT06648902 ↗ |
| Modality | Small molecule | — CHEMBL2104708 ↗ |
| Route | Intramuscular | “First group received intramuscularly with the dosage regimen of 5 mL of solution (500 mg of ethyl methyl hydroxypyridine succinate + 500 mg of meldonium) once per day for 10...” NCT05689827 ↗ |
| Route | Oral | “First group received intramuscularly with the dosage regimen of 5 mL of solution (500 mg of ethyl methyl hydroxypyridine succinate + 500 mg of meldonium) once per day for 10...” NCT05689827 ↗ |